U.S., European Union and other antitrust enforcers are teaming up to overhaul how they weigh pharmaceutical mergers in a move that could curb transactions seen as raising prices or dampening innovation.
The Federal Trade Commission and the Justice Department will work with the European Commission, the U.K.’s Competition and Markets Authority and the Canadian Competition Bureau to identify ways to scrutinize deals more closely, according to emailed press releases from the FTC and the EU. Three state attorneys general will also join the group, the statement said.
